Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience

Autor: Michael J. Krowka, Hilary M. DuBrock, Gurpreet S. Sandhu, Ryoji Yanagisawa, Vidhu Anand, Robert P. Frantz, Garvan C. Kane
Rok vydání: 2019
Předmět:
medicine.medical_specialty
BPA
balloon pulmonary angioplasty
medicine.medical_treatment
PH
pulmonary hypertension
Hemodynamics
030204 cardiovascular system & hematology
Balloon
Single Center
Riociguat
TAPSE
tricuspid annular plane systolic excursion
03 medical and health sciences
0302 clinical medicine
Interquartile range
Angioplasty
medicine.artery
Internal medicine
RVSP
right ventricular systolic pressure
medicine
RHC
right-sided heart catheterization
030212 general & internal medicine
NYHA
New York Heart Association
IQR
interquartile range
CTEPH
chronic thromboembolic pulmonary hypertension
lcsh:R5-920
NT-proBNP
N-terminal pro-B-type natriuretic peptide
business.industry
medicine.disease
ICU
intensive care unit
Pulmonary hypertension
PA
pulmonary artery
6MWD
6-minute walk distance
WU
Wood units
Pulmonary artery
Cardiology
Original Article
RAP
right atrial pressure
RV
right ventricular
lcsh:Medicine (General)
business
medicine.drug
Zdroj: Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 3, Iss 3, Pp 311-318 (2019)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
ISSN: 2542-4548
DOI: 10.1016/j.mayocpiqo.2019.06.006
Popis: Objective: To evaluate the safety and efficacy of balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) seen at a US medical center. Patients and Methods: Patients with inoperable or residual postendarterectomy CTEPH who underwent BPA at Mayo Clinic in Rochester, Minnesota, between August 11, 2014, and May 17, 2018, were included. Invasive hemodynamic, clinical, laboratory, and echocardiographic data were collected and analyzed retrospectively. Results: We identified 31 patients (26 with inoperable CTEPH and 5 with residual postendarterectomy CTEPH) who underwent 75 BPA procedures performed in a staged manner to reduce complications. The median number of sessions was 2 (interquartile range [IQR], 1-3) per patient, and the number of vessels treated per session was 3 (IQR, 2-3). Of the 31 patients, 24 (77.4%) were taking pulmonary vasodilators and 22 (71.0%) were taking riociguat. The mean pulmonary arterial pressure decreased from 40 mm Hg (IQR, 29-48 mm Hg) to 29 mm Hg (IQR, 25-37 mm Hg; P
Databáze: OpenAIRE
Externí odkaz: